66
Participants
Start Date
May 31, 2008
Primary Completion Date
December 31, 2011
Study Completion Date
January 31, 2012
HGS1029
Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
The Sarah Cannon Research Institute, Nashville
University of Colorado Health Sciences Center, Aurora
Stanford University Dept. of Medicine-Oncology, Stanford
Lead Sponsor
Human Genome Sciences Inc.
INDUSTRY